[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bioxytran Inc (BIXT)

Bioxytran Inc (BIXT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 3,917
  • Shares Outstanding, K 114,195
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,120 K
  • EBIT $ -3 M
  • EBITDA $ -3 M
  • 60-Month Beta 1.95
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.02
  • Most Recent Earnings $-0.02 on 05/15/26
  • Next Earnings Date 08/10/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0290 +3.45%
on 05/05/26
0.0376 -20.21%
on 05/08/26
-0.0050 (-14.29%)
since 04/24/26
3-Month
0.0262 +14.50%
on 03/18/26
0.0544 -44.85%
on 03/30/26
-0.0121 (-28.74%)
since 02/26/26
52-Week
0.0262 +14.50%
on 03/18/26
0.1600 -81.25%
on 05/29/25
-0.1216 (-80.21%)
since 05/23/25

Most Recent Stories

More News
BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT

Financing strengthens balance sheet and supports advancement of key development initiatives NEWTON, MA, March 20, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTC: BIXT), a clinical-stage biotechnology...

BIXT : 0.0300 (-12.54%)
Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19

BOSTON, MA / ACCESS Newswire / March 2, 2026 / Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics, today announced results from a randomized,...

BIXT : 0.0300 (-12.54%)
Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus

Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus

BIXT : 0.0300 (-12.54%)
Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement

Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement

BIXT : 0.0300 (-12.54%)
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran

BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. ( OTCQB: BIXT ) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled,...

BIXT : 0.0300 (-12.54%)
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran

Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran

BIXT : 0.0300 (-12.54%)
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics

NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform technologies...

BIXT : 0.0300 (-12.54%)
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics

Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics

BIXT : 0.0300 (-12.54%)
Bioxytran Provides Corporate Update Highlighting Momentum Across Its Multi-Platform Pipeline

Bioxytran Provides Corporate Update Highlighting Momentum Across Its Multi-Platform Pipeline

BIXT : 0.0300 (-12.54%)

Business Summary

BioXyTran Inc. is a biotechnology company. It develops anti-necrosis drugs to treat medical conditions resulting from ischemia. The company's product pipeline consists of BXT-25 and BXT-252 which are in clinical stage. BioXyTran Inc. is based in Newton, United States.

See More

Key Turning Points

3rd Resistance Point 0.0370
2nd Resistance Point 0.0356
1st Resistance Point 0.0328
Last Price 0.0300
1st Support Level 0.0286
2nd Support Level 0.0272
3rd Support Level 0.0244

See More

52-Week High 0.1600
Fibonacci 61.8% 0.1089
Fibonacci 50% 0.0931
Fibonacci 38.2% 0.0773
Last Price 0.0300
52-Week Low 0.0262

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.